Gastric Cancer Cancer Gastric
Conditions
Interventions
1. Arm A: Ranitidine 50 mg in 20 ml 0.9% saline or 5% dextrose to be given intravenously three times daily until oral treatment is tolerated. This will be followed by ranitidine 150 mg tablet twice da
Sponsors
Glaxo Wellcome (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged <18 years 2. Gastric cancer proven by histology and endoscopy or barium meal 3. Patients selected for laparotomy must commence intravenous treatment with study drug at the time of induction of anaesthesia 4. Adequate renal function 5. No previous resection for gastric cancer 6. No other prior or concurrent malignancy 7. No treatment with systemic steroids, hormones or other know immunomodulating drugs within the last 7 days prior to the start of the study period 8. No medical contraindications to study treatments
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed